

Remarks

The Examiner has required that applicants elect a single invention to which the claims must be restricted.

Applicants elect Group II without traverse. Group II, claims 4, 5 and 8 are drawn to a method for identifying an agent and using said agent that interferes with T cell activation and/or -differentiation and/or modulation of other inflammatory effector cells

Elected claim 4 is currently amended. Claims 1-3, 6-7 and 9-10 have been withdrawn in response to the restriction requirement. No new matter has been introduced. Applicants reserve their right to file a divisional(s) on any material withdrawn as a result of this restriction requirement.

In view of the remarks and the amendments, further and favorable consideration of the present application and the allowance of all pending claims are respectfully requested. The Examiner is also invited to contact the undersigned should the Examiner believe that such contact would expedite prosecution of the present application.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: July 25, 2006